FUTURE HEALTH
BADGE
® PRECISION GENE DELIVERY PLATFORM
DNA / RNA delivery platform enables precision targeting of gene expression
RESEARCH GROUP
BaDGE ® Targeted Gene Delivery Platform , a long-standing collaboration between UNSW Translational Neuroscience Facility and Biomedical Engineering Teams , is poised for spinout in Q4 2024 . BaDGE ® is a patented ‘ electro-lens ’ technology utilising focused pulsed electric fields for ( non-viral ) precision gene electrotransfer ( GET ) of naked DNA and mRNA .
BaDGE Inc . will be established to provide GMP device manufacture of the patented BaDGE ® GET devices , and development of proprietary mRNA and ' naked ' DNA molecules for hearing , vision , brain , and nerve / muscle repair applications . These applications are currently in advanced pre-clinical and first-in-human ( phase 1 / 2a ) clinical trial , supported by federal ( including Australia ' s Economic Accelerator ), state , philanthropic and industry funding .
BaDGE ® Inc . is modelled to extend in-house and industry partner therapeutics programs to clinical trials , including wet AMD , refractory focal epilepsy , nerve repair , intra-tumoral oncology applications , building rapid global impact .
> Cochlear implant patients in a first-in-human clinical trial achieved improved hearing from BaDGE ® gene electrotransfer of DNA encoding neurotrophins , directed to regrowing the cochlear nerve to optimise the bionic ear neural interface .
> BaDGE ® GET electrical charge transfer is minimised by proprietary electro-lens electric field focusing and by local control of conductivity to achieve highly efficient and safe gene expression ; evidenced by breakthrough focal expression in the brain .
> Proven highly effective for mRNA delivery , driving reporter protein expression in muscle in under three hours , making this ideal for precision gene-based treatments for neural and other time-critical injuries .
• 35